Congressman Takes Unpaid Gig to Oversee Drug Company Trial

0
491

Rep. Andy Harris Denounced Stay At Home Orders and ‘Cult of Masks’

Health Editor’s Note: A five-time republican congressman has joined the hunt for coronavirus treatments as he is overseeing NeuroRx drug company trial. His close ties to NeuroRx CEO, Jonathan Javitt, could create issues of bias. Also called into question is his lack of experience in evaluating data from drug trials. Another instance of putting the fox into the hen house?  Why not, it is the way the U.S. has been doing business under Trump. Who cares if it involves human lives?. Is this ethical because he is not receiving a salary for this position?. I think not!…Carol   

 

Biography
Carol graduated from Riverside White Cross School of Nursing in Columbus, Ohio and received her diploma as a registered nurse. She attended Bowling Green State University where she received a Bachelor of Arts Degree in History and Literature. She attended the University of Toledo, College of Nursing, and received a Master’s of Nursing Science Degree as an Educator.

She has traveled extensively, is a photographer, and writes on medical issues. Carol has three children RJ, Katherine, and Stephen – one daughter-in-law; Katie – two granddaughters; Isabella Marianna and Zoe Olivia – and one grandson, Alexander Paul. She also shares her life with husband Gordon Duff, many cats, and two rescue pups.

Carol’s Archives 2009-2013
ATTENTION READERS
Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy